Naltrexone: Nursing Drug Guide, Opioid Withdrawal Risk & Hold Rules
Healthcare medication guide: verify a true 7–10 day opioid-free interval before every start—precipitated withdrawal can be severe if naltrexone is given too soon, and patients who use opioids to overcome blockade risk fatal overdose.
Naltrexone is a pure opioid antagonist. Giving it to a patient who is not opioid-free for 7–10 days can precipitate severe opioid withdrawal. After blockade is established, opioid analgesics are ineffective at usual doses—and patients who attempt to overcome the blockade with high opioid doses risk fatal overdose. Hold the dose when opioid exposure is unclear, verify with urine drug screening and prescriber-directed naloxone challenge per protocol, and monitor for hepatotoxicity throughout therapy.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Do not administer naltrexone until the patient has been opioid-free for 7–10 days and verification is complete. One dose given too early can trigger abrupt, severe withdrawal; after blockade, standard opioid doses may not treat pain and high-dose opioid attempts can be fatal.
Most common brand names
Naltrexone is available as oral tablets and as extended-release injectable formulations in some regions. Always verify the ordered product, strength, and indication on the MAR.
Common brand names include Revia (oral) and Vivitrol (extended-release injectable naltrexone). Combination weight-management products containing naltrexone exist (e.g., Contrave with bupropion)—do not confuse single-entity naltrexone orders with combination tablets.
Why we give it — Indications
Naltrexone supports recovery from alcohol use disorder and blocks opioid effects in patients who have completed opioid detoxification. Nursing focus is safe initiation—not speed.
| Use | Detail |
|---|---|
| Alcohol dependence | Adjunct to support abstinence from alcohol in motivated patients; 50 mg once daily per labeling. |
| Opioid blockade after detox | Maintenance after opioid-free verification to prevent relapse; start 25 mg on day 1, then 50 mg daily. Not a substitute for methadone or buprenorphine maintenance therapy. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Naltrexone is a competitive opioid antagonist at mu and kappa receptors. It displaces opioids from receptors—if opioids are still present, withdrawal symptoms can appear abruptly (precipitated withdrawal). With chronic use, euphoria and analgesic effects of opioids and some opioid-containing cough/cold products are blocked, reducing relapse risk but also eliminating therapeutic opioid analgesia.
Dosing overview
Verify indication, opioid-free status, and hepatic function before the first dose. Dosing below reflects the reviewed DailyMed oral labeling.
Missed dose: Do not double the next dose. Give the next scheduled dose when due. If the patient used opioids during a lapse, hold and re-verify opioid-free status before restarting—precipitated withdrawal risk returns.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak (oral) | Approximately 1 hour | Withdrawal precipitation, if it occurs, may be rapid after the first dose when opioids are still present |
| Half-life | ~4 hours (parent); ~13 hours (active metabolite 6-β-naltrexol) | Blockade persists beyond a single dose—plan analgesia without opioids when naltrexone is active |
| Duration of blockade | Not specified as a single numeric value in labeling summary | Assume ongoing opioid antagonism while therapy continues; document blockade in MAR safety fields |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm 7–10 day opioid-free interval with history, medication reconciliation, and urine drug screen
- Complete prescriber-directed naloxone challenge when ordered—positive challenge means hold naltrexone
- Review hepatic history (cirrhosis, hepatitis B), baseline AST/ALT, and eGFR when clinically indicated
- Screen for hidden opioids: hydrocodone, oxycodone, morphine, cough syrups, and illicit opioids
Contraindications
- Current opioid dependence or patients in acute opioid withdrawal
- Any current opioid analgesic use (therapeutic or illicit)
- Positive urine screen for opioids or positive naloxone challenge
- Known hypersensitivity to naltrexone
- Acute hepatitis or liver failure
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Opioid analgesics & opioid-containing products | Opioid effects blocked; higher doses attempted to overcome blockade may cause fatal overdose | Document blockade; coordinate non-opioid pain assessment and analgesia plan with prescriber |
| Disulfiram | Combined hepatotoxicity risk per labeling | Monitor LFTs closely; report abdominal pain or jaundice; avoid starting combination without specialist review |
| Thioridazine | Increased somnolence when combined with naltrexone per labeling | Monitor sedation and mental status; fall precautions |
On a small screen, swipe or scroll sideways to see the full table.
Administration
- Oral tablets: may be given with food if GI upset occurs; swallow whole unless pharmacy approves splitting per formulation
- First opioid-dependence dose is often 25 mg, then 50 mg daily—verify both orders on the MAR
- Do not administer until opioid-free verification is documented in the chart
Patients eager to start recovery may minimize recent opioid use. Reconcile PRN analgesics, discharge prescriptions, cough medicines, and illicit use before the first tablet. When in doubt, hold and clarify.
Expected therapeutic response
- Reduced alcohol craving and sustained abstinence when used as part of a comprehensive recovery plan
- Blocked euphoric effect if opioids are used—patients should report diminished opioid “high”
- No sedation from naltrexone itself—new somnolence may signal interaction (e.g., thioridazine) or withdrawal
Red flags — Stop and act
Escalate immediately for precipitated withdrawal, hepatotoxicity, or attempted opioid overdose to overcome blockade.
- Sudden severe abdominal pain, nausea, vomiting, myalgias, lacrimation, or agitation after a dose—possible precipitated withdrawal
- Jaundice, dark urine, or rising transaminases—possible hepatocellular injury; evaluate for acute liver failure
- Respiratory depression after large opioid use—treat as opioid overdose emergency per protocol; naltrexone does not prevent all overdose mechanisms
- Patient reports using opioids or alcohol heavily to overcome blockade—urgent addiction medicine and safety planning
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Precipitated opioid withdrawal | Serious if opioids not cleared | Hold further naltrexone; notify prescriber; monitor vitals and withdrawal symptoms; supportive care per protocol |
| Nausea, headache, nervousness, insomnia | Common in clinical trials | Supportive care; differentiate from withdrawal or hepatic injury |
| Hepatocellular injury | Serious; labeling warning | Hold drug; notify prescriber; obtain LFTs; evaluate for acute hepatitis |
| Anxiety / depression | Reported | Screen mood; coordinate behavioral health; assess suicide risk per unit protocol |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Naltrexone overdose in adults produces few clinical symptoms per labeling—no antidote is specified. Supportive care is recommended. The greater nursing emergency is often opioid overdose in a patient attempting to overcome receptor blockade: treat per opioid overdose protocol, support respirations, and contact local poison control or toxicology services per facility policy.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance—do not rely on country-specific hotlines in patient-facing teaching.
Look-alike / sound-alike and error prevention
- Naltrexone vs naloxone—antagonists with different roles; naloxone challenge tests opioid occupancy, naltrexone maintains blockade
- Naltrexone vs buprenorphine/naloxone (Suboxone)—partial agonist maintenance vs pure antagonist after detox
- Revia vs Contrave—verify whether order is naltrexone alone or naltrexone/bupropion combination
- 50 mg vs 25 mg—confirm day-1 opioid-dependence dose before administration
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Opioid-free verification | Document last opioid use date/time, UDS result, and naloxone challenge outcome before first dose. |
| Surgery / procedures | Plan non-opioid analgesia with anesthesia and surgical teams—standard opioids may be ineffective. |
| Carry identification | Encourage medical alert documentation that patient is on opioid antagonist therapy. |
| Commonly missed | PRN hydrocodone or oxycodone from another provider; cough syrups; illicit fentanyl analogues not on MAR. |
| Ask pharmacy when | Unclear opioid-free interval, positive UDS, hepatic lab abnormalities, or disulfiram co-therapy. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Recent opioid use / incomplete detox | Highest risk for precipitated withdrawal—hold until 7–10 days opioid-free and verification complete. |
| Hepatic disease | Contraindicated in acute hepatitis or liver failure; hepatotoxicity warning—baseline and periodic LFTs per protocol. |
| Pregnancy (category C) | Animal data show fetal risk; human data limited—use only if benefit outweighs risk with specialist coordination. |
| Lactation | Labeling advises caution; consult LactMed and prescriber—balance breastfeeding benefits with infant exposure. |
| Pediatrics (<18 years) | Not indicated per labeling—do not administer without specialist exception and institutional policy. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Withdrawal signs after first doses (pulse, blood pressure, diaphoresis, GI symptoms, restlessness)
- Hepatic panel trend (AST, ALT) and clinical jaundice
- Alcohol and opioid use reports, urine drug screens per protocol, and mood screening when clinically indicated
Document
- Opioid-free start date, verification method, and prescriber clearance for initiation
- Patient education on blockade, ineffective opioid analgesia, and overdose risk if opioids are misused
- Any hold events with prescriber/pharmacist notification
Patient teaching
- You must be completely off opioids for 7–10 days before starting—tell your team about every opioid, including patches, cough medicine, and illicit drugs
- After naltrexone starts, usual opioid doses will not work for pain—plan procedures and injuries with your care team in advance
- Using large amounts of opioids to “break through” the blockade can cause fatal overdose
- Report abdominal pain, yellow skin or eyes, dark urine, or worsening mood immediately
- Carry information that you are on an opioid blocker so emergency teams choose appropriate analgesia
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Patient is not opioid-free for 7–10 days or last opioid use is unclear
- Current opioid dependence, acute withdrawal, or any ongoing opioid analgesic therapy
- Positive urine opioid screen or positive naloxone challenge
- Known naltrexone allergy
- Acute hepatitis or liver failure; significant hepatic injury signs or rapidly rising transaminases
- Patient reports using opioids since the last verified opioid-free date
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Naltrexone is a commitment device—not a detox agent. Nurses protect patients at the handoff between detox completion and maintenance blockade.
1. Check-before-you-give protocol
- Right patient, right drug, right dose—and right opioid-free interval
- Reconcile MAR, home meds, and illicit use history on every start and restart
- Confirm negative UDS and documented naloxone challenge when ordered
- Verify hepatic labs and allergy status before day-1 dose
2. High-alert mindset
Opioid antagonist — precipitated withdrawal and fatal overdose riskTreat initiation like a high-risk medication pass: independent verification of opioid-free status and prescriber clearance before the first tablet.
3. Clinical workflow: hold and question rules
- If the patient used hydrocodone, oxycodone, morphine, methadone, buprenorphine, or illicit opioids within 10 days—hold and call pharmacy
- If the patient needs urgent surgery—coordinate non-opioid analgesia; do not assume PRN opioids will work
- If precipitated withdrawal is suspected—stop naltrexone, notify prescriber, monitor closely per withdrawal protocol
4. Critical teach-back questions
- “How long must you be completely off opioids before your first naltrexone dose?” (Patient should state 7–10 days and name verification steps.)
- “What happens if you take opioid pain medicine while on naltrexone?” (Patient should state opioids may not work and that large doses to overcome blockade can cause fatal overdose.)
5. Care coordination
Pharmacist: Opioid-free verification, interaction review (disulfiram, thioridazine), and hepatic monitoring plan
Addiction medicine / prescriber: Initiation timing, naloxone challenge interpretation, and relapse response planning
🧠 Quick mental checklist
- Has this patient been opioid-free for 7–10 days with documented verification?
- Is the urine screen negative and naloxone challenge negative per protocol?
- Are AST/ALT acceptable and is acute hepatitis ruled out?
- Does the patient understand opioid blockade and fatal overdose risk if they use opioids?
- If any recent opioid use is reported, have I held the dose and called pharmacy?
Naltrexone NCLEX practice questions
This NCLEX-style clinical judgment practice set for naltrexone uses a tabbed outpatient case (MAR, labs, history, nursing notes), then rotates priority action, cue recognition (SATA), withdrawal trend interpretation, matrix urgency sorting, emergency analgesia judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Naltrexone 50 mg PO daily — scheduled 0900, held (awaiting verification)
- Acetaminophen 650 mg PO q6h PRN mild pain — not given
- 0905: prescriber order “Naltrexone 25 mg day 1 if opioid-free verified”
- 0800 urine drug screen: positive for opiates (repeat collection ordered)
- Baseline hepatic panel: AST 24 U/L, ALT 28 U/L (WNL)
- Naloxone challenge: not yet performed
- 34-year-old outpatient program intake for alcohol use disorder
- Reports last hydrocodone 5 mg use 3 days ago for dental pain
- Goal: start naltrexone today to support alcohol abstinence
- No known drug allergies
- 0845: Patient eager to begin; states “I only took one pain pill this week”
- 0850: Admission reconciliation incomplete—home medicine list not yet verified with pharmacy
- 0900: Nurse reviewing case tabs before first dose; positive UDS noted
Answer key & rationale
Frequently asked questions
When should a nurse hold naltrexone?
Hold when the patient is not opioid-free for 7–10 days, has current opioid dependence or acute withdrawal, positive urine opioid screen or positive naloxone challenge, uses opioid analgesics, has acute hepatitis or liver failure, known allergy, or recent opioid use is unclear on reconciliation.
How long must a patient be opioid-free before starting naltrexone?
Prescribing information requires 7–10 days without opioids. Verify with history, medication reconciliation, urine drug screening, and often a naloxone challenge per prescriber protocol.
What hepatotoxicity monitoring do nurses watch for?
Labeling warns of hepatocellular injury. Monitor for abdominal pain, nausea, vomiting, jaundice, dark urine, and rising AST/ALT. Contraindicated in acute hepatitis or liver failure; obtain baseline and follow-up liver function tests per protocol.
Can emergency opioid analgesics work if a patient is on naltrexone?
Opioid effects are blocked. Standard doses may not relieve pain, and large doses to overcome blockade risk fatal overdose. Coordinate non-opioid analgesia with the prescriber and document blockade per facility policy.
Is naltrexone safe in pregnancy?
Pregnancy category C per labeling—animal studies showed fetal risk and human data are limited. Use only if potential benefit justifies risk with specialist involvement.
What should nurses do for a missed naltrexone dose?
Do not double the next dose. Give the next scheduled dose when due. If opioids were used during the lapse, hold and re-verify opioid-free status before restarting.
References
-
U.S. National Library of Medicine. Naltrexone — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c7da2bc-e2c1-48f6-8c3f-287119b427e2
-
Drugs and Lactation Database (LactMed). Naltrexone. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK437134/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.